In order to provide our clients with the most comprehensive service offer, Active Biomarkers has developed partnerships with targeted companies and institutes. Developing our panel of technologies and solutions, offering more preclinical models and strengthening our geographical presence are our key partnering drivers. We invite you to discover some of our partners and their domains of expertise.
Cynbiose is a specialty Contract Research Organization (CRO) unique in Europe. The company is specialized in preclinical research services with a core expertise and focus on the non-human primate (NHP) model, including the development of innovative clinically relevant models across multiple therapeutic areas to accelerate the discovery of drug candidates.
As preferred partners since more than 10 years, Cynbiose and Active Biomarkers can support you on
- exploratory pharmacokinetics and pharmacodynamics studies
- early (non-GLP) safety studies
- hybrid exploratory designs
- efficacy studies to bridge the gap between preclinical and clinical development
PhinC Development is the expert partner for small to medium sized pharmaceutical or biotech companies, who need to move forward in early drug research.
PhinC Development helps to take the best decisions concerning drug development using all existing pharmacology and pharmacometrics modeling & simulation (M&S) tools. The application of the MIDD concept "Model Informed Drug Development" will significantly optimize the development of your drug candidate at different levels by:
- Providing essential data on the product under study from the earliest stages of development
- Strengthening scientific justifications during regulatory submissions
- Optimizing time and means to implement
For more than 20 years, Banook Group is one of the few established international providers capable of supplying Cardiac Safety, Central Imaging, Endpoint Adjudication and eCOA/ePRO solution services.
By using its medical and regulatory expertise and direct-to-patient innovative solutions, Banook Group became a key player for pharmaceutical, CROs, biotech companies, medical device and nonprofit organizations during clinical trials.
With more than 2.600 equipped sites, Banook Group is particularly involved to spread its know-how over the world, including in emergent countries to support the research for neglected diseases
L’AFSSI, l’Association Française des Sociétés de Services et d’Innovation pour les Sciences de la Vie est née en 2012 de la volonté de fédérer les sociétés françaises de services et d’innovation technologique dans le domaine stratégique des Sciences du Vivant.
Une large représentation sectorielle en Santé
L’AFSSI vise à regrouper tous les secteurs de la biotechnologie, chimie, environnement, cosmétologie, agroalimentaire, bioinformatique, et inclut le diagnostic et les essais cliniques.
Animateurs clés du développement des sciences du vivant, les entrepreneurs porteurs de projets matures se sont organisés pour une meilleure prise en considération de leurs problématiques de croissance afin que la filière et ses membres, dans leur ensemble, gagnent en ampleur et en compétitivité. L’AFSSI vient compléter la représentation des acteurs dans l’écosystème des Sciences de la Vie.
MabDesign is an organization dedicated to the creation of a unique environment that allows the economic development and growth of the French industrial sector in the field of therapeutic antibodies and immunotherapies.
MabDesign aims to structure the French sector by promoting networking and support the stakeholder’s skills development. To attain this goal, MabDesign is deploying several actions:
- Build and implement a unique nationwide directory of antibody stakeholders allowing the identification of expertise and potential partners.
- Mobilize and support a scientific and industrial network through regular conferences and workshops, thus promoting innovation and networking between high-profile experts.
- Provide access to innovative and dedicated technological and scientific training solutions and skills development support according to the sector requirements.
As a Cluster, Lyonbiopole is the gateway to healthcare innovation in the Auvergne-Rhône-Alpes region.
It’s supporting ambitious projects and innovative companies in the healthcare & life sciences’ sector. Its aim is to help innovators develop new technologies, products and services in a push toward a more personalized medicine and better treatments for patients.
Created in April 2012 by the Institut Pasteur and Lyonbiopole health competitiveness cluster, following the initiative of the French government, BIOASTER Technological Research Institute (TRI) is working to develop an unique technological and innovative model to support the latest challenges in microbiology, in particular to fight antimicrobials resistance, improve vaccines safety and efficacy, quickly diagnose infections at patient bedside and take full advantage of human and animal microbiota.
In order to overcome technological bottlenecks and explore new avenues, BIOASTER is leading collaborative projects that bring together academics, start-ups, SMEs and industrial groups that rely on t support of the French Government through the "Investissements d'Avenir" , infrastructures funded by regional authorities (Lyon Metropolis and the Auvergne-Rhône-Alpes Region), world-class academics and industries : (the Institute Pasteur, CEA, CNRS, Inserm, Danone Nutricia Research, Institut Mérieux and Sanofi Pasteur) and from highly dynamic SMEs and regional cluster.